At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
OC000459drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study
In Brief
A Phase 2 clinical trial evaluating OC000459 for Atopic Dermatitis. Completed, enrolled 142 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedDec 2013
Primary CompletionSep 2015
Study CompletionFeb 2016
TodayJul 2026
First PostedDec 5, 2013
Enrollment StartOct 1, 2013
Primary CompletionSep 1, 2015
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.6 years ago
Interventions
OC000459drug
Oral CRTH2 antagonist